Sparks - Alzinova

Alzinova has received Fast Track designation from the US Food and Drug Administration (FDA) for its therapeutic vaccine ALZ-101, targeting toxic amyloid-beta oligomers in Alzheimer’s disease (AD). The ALZ-101 treatment combines Alzinova’s AβCC Peptide Technology with immunotherapy, stopping Aβ42 plaque build-up on synapses and preventing neuron loss responsible for the symptoms of AD. We see this as an encouraging development for the company, allowing it to collaborate with the FDA with more frequent interactions and reviews, potentially supporting faster approval, should data continue to be encouraging. Note that Alzinova recently received the FDA approval for its planned Phase II study for ALZ-101. The study will be a multi-centre trial (n=240) evaluating safety, tolerability and efficacy in patients with early-onset AD.

In March 2025, Alzinova presented promising Phase Ib safety and efficacy data, showing early clinical benefit and supportive mechanistic evidence in 26 patients followed for at least 30 weeks. Exploratory research conducted as part of the study, assessing AD-related biomarkers, immune response and changes in cognition, showed a stable disease profile with no signs of degradation.